1. Home
  2. LYEL vs ZNTL Comparison

LYEL vs ZNTL Comparison

Compare LYEL & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

SELL

Current Price

$13.64

Market Cap

195.8M

Sector

Health Care

ML Signal

SELL

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$1.37

Market Cap

165.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LYEL
ZNTL
Founded
2018
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
195.8M
165.1M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
LYEL
ZNTL
Price
$13.64
$1.37
Analyst Decision
Buy
Strong Buy
Analyst Count
8
11
Target Price
★ $37.63
$7.44
AVG Volume (30 Days)
212.6K
★ 1.3M
Earning Date
11-04-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 18.03
EPS
N/A
★ N/A
Revenue
★ $36,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$7.20
$1.30
52 Week High
$45.00
$6.95

Technical Indicators

Market Signals
Indicator
LYEL
ZNTL
Relative Strength Index (RSI) 54.63 23.27
Support Level $12.25 N/A
Resistance Level $14.97 $1.98
Average True Range (ATR) 1.67 0.18
MACD -0.18 -0.01
Stochastic Oscillator 43.74 8.82

Price Performance

Historical Comparison
LYEL
ZNTL

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: